JPRN-UMIN000052861已完成Unknown
A placebo controlled, double blind, comparative trial concerning safety verification of long-term intake of protein hydrolyzate - A placebo controlled, double blind, comparative trial concerning safety verification of long-term intake of protein hydrolyzate
IMEQRD Co., Ltd0 个研究点目标入组 30 人开始时间: 2023年12月12日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Individuals currently taking commercial pharmaceuticals and quasi-drugs, health foods and supplements aimed at maintaining and recovering health, and unable to discontinue use during the trial period. 2. Individuals who have participated in experiments consuming other foods or using pharmaceuticals, applying cosmetics and pharmaceuticals etc. within one month from the day of consent, or intends to participate in other trials during this trial. 3. Individuals who consume large amounts of alcohol (equivalent to 40 g or more of alcohol per day). 4. Individuals with irregular lifestyles such as shift work, night work, etc. 5. Individuals with smoking habits (those who are less than one year after quitting). 6. Individuals planning major lifestyle changes (diet, sleep, exercise habits etc.) during the trial period, such as long trips. 7. Individuals who consume large amounts of milk, dairy products, or protein foods derived from milk every day (for example, over 1 L / day of milk, over 500 g / day of yogurt, or over 20 g / day of protein foods). 8. Individuals who have undergone gastrointestinal surgery, however, appendectomy is acceptable. 9. Individuals currently under treatment with any medications or Chinese medicines, however, instant use is acceptable. 10. Individuals with serious liver, kidney, heart, respiratory, endocrine, metabolic diseases, mental illnesses, or higher brain dysfunction. 11. Individuals with a history of treatment for heart failure, myocardial infarction, etc. 12. Individuals who have experienced discomfort or health deterioration, or vasovagal reflex due to blood collection. 13. Individuals likely to show symptoms of milk/soy allergy, or who have lactose intolerance. 14. Individuals with a current or history of drug or food allergies. 15. Individuals currently pregnant or breastfeeding, or wishing to become pregnant during the trial period. 16. Individuals deemed inappropriate as research subjects by the study's principal investigator.
研究者
相似试验
尚未招募
2 期
A Clinical Trial to study the efficacy & safety of Colebrookea Oppositifolia (Aceteoside) in acute hepatitis patients.CTRI/2008/091/000090Council of Scientific & Industrial Research200
进行中（未招募）
不适用
A randomized, double-blind, placebo comparative clinical trial to evaluate the functionality and safety of KPE01 and KPE02 for body fat reduction in overweight or obese adults.Endocrine, nutritional and metabolic diseasesKCT0007879Semyung University150
尚未招募
2 期
Evaluate the efficacy and safety of PartySmart Soft ChewsCTRI/2022/05/042617Himalaya Wellness Company
进行中（未招募）
不适用
Flora to provide confirmation: A study evaluating the efficacy of QGE031 compared to omalizumab in patients with allergic asthma.MedDRA version: 14.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersasthmaEUCTR2012-003350-84-SEovartis Pharma Services AG40
已完成
不适用
clinical trial for the patients with degenerative disc diseaseDiseases of the musculo-skeletal system and connective tissueKCT0001037Yuhan48